Back to search

Article

Long-term outcomes and neutralising antibody kinetics after Tixagevimab/Cilgavimab prophylaxis in haematological patients: a real-world cohort study in Japan

2026-05-04

Abstract excerpt

<title>Abstract</title> <p>Patients with haematological diseases remain vulnerable to COVID-19 despite vaccination. We conducted a prospective, real-world cohort study at a single Japanese centre, evaluating long-term outcomes and neutralising antibody kinetics after tixagevimab/cilgavimab (T/C) as pre-exposure prophylaxis. Between October 2022 and December 2023, 179 patients (236 doses) were followed for a media...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d7074e71-839b-576b-b24f-a1678fb0ece4
DOI
10.21203/rs.3.rs-8141059/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Long-term outcomes and neutralising antibody kinetics after Tixagevimab/Cilgavimab prophylaxis in haematological patients: a real-world cohort study in JapanDOI 10.21203/rs.3.rs-8141059/v1
Pre-exposure prophylaxis for COVID-19 with Tix-agevimab/Cilgavimab in kidney transplant recipients in the Kraken variant (XBB.1.5) era: A Single-center ExperienceSemantic proximity
Evaluation of neutralizing capacity of tixagevimab plus cilgavimab: a case-series study with comparison to a vaccinated populationSemantic proximity
Unveiling Protection: A Meta-Analysis of Tixagevimab-Cilgavimab Prophylaxis in 28,950 Transplant Recipients and Immunocompromised Patients Against COVID-19Semantic proximity
Systematic review of the clinical effectiveness of Tixagevimab/Cilgavimab for prophylaxis of COVID-19 in immunocompromised patientsSemantic proximity
Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron EraSemantic proximity
Complex intra-host SARS-CoV-2 evolution following monoclonal antibody pre-exposure prophylaxisSemantic proximity
Tixagevimab/Cilgavimab for Treatment of Hospitalised COVID-19 Patients: A Randomised, Double-Blind, Phase 3 TrialSemantic proximity
Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From the CANOPY Clinical TrialSemantic proximity
A statistical immune correlates of protection model for predicting efficacy from neutralizing antibody titers to establish immunobridging of monoclonal antibodies for prevention of COVID-19Semantic proximity
Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trialSemantic proximity
Tixagevimab/Cilgavimab for Prevention of COVID-19 during the Omicron Surge: Retrospective Analysis of National VA Electronic DataSemantic proximity
Breakthrough Covid-19 cases despite tixagevimab and cilgavimab (Evusheld™) prophylaxis in kidney transplant recipientsSemantic proximity
Select a neighboring publication to make it the new centre.